Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in industrialized countries because of the worldwide epidemic of obesity. Beyond metabolic complications, a subset of patients with NAFLD develop non-alcoholic steatohepatitis (NASH) with fibrosis, which is emerging as a leading cause of liver transplantation due to progression to cirrhosis and cancer. For these reasons, NAFLD is considered a public health burden. In recent years endoscopic bariatric and metabolic therapies (EBMT) have emerged as safe and effective for the treatment of obesity and type 2 diabetes mellitus. EBMT include gastric and duodenal devices and techniques such as intragastric balloons, endoscopic sleeve gastroplasty, endoscopic small bowel by-pass and duodenal mucosal resurfacing. Observational studies and pilot trials have revealed beneficial effects of EBMT on NAFLD as assessed by non-invasive parameters or histology. In this review we summarise current evidence for the efficacy and safety of EBMT in obese patients with NAFLD and examine future clinical applications.

Salomone, F., Sharaiha, R. Z., Boskoski, I., Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: Evidence and perspectives, <<LIVER INTERNATIONAL>>, 2020; 40 (6): 1262-1268. [doi:10.1111/liv.14441] [http://hdl.handle.net/10807/166544]

Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: Evidence and perspectives

Boskoski, Ivo
2020

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in industrialized countries because of the worldwide epidemic of obesity. Beyond metabolic complications, a subset of patients with NAFLD develop non-alcoholic steatohepatitis (NASH) with fibrosis, which is emerging as a leading cause of liver transplantation due to progression to cirrhosis and cancer. For these reasons, NAFLD is considered a public health burden. In recent years endoscopic bariatric and metabolic therapies (EBMT) have emerged as safe and effective for the treatment of obesity and type 2 diabetes mellitus. EBMT include gastric and duodenal devices and techniques such as intragastric balloons, endoscopic sleeve gastroplasty, endoscopic small bowel by-pass and duodenal mucosal resurfacing. Observational studies and pilot trials have revealed beneficial effects of EBMT on NAFLD as assessed by non-invasive parameters or histology. In this review we summarise current evidence for the efficacy and safety of EBMT in obese patients with NAFLD and examine future clinical applications.
2020
Inglese
Salomone, F., Sharaiha, R. Z., Boskoski, I., Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: Evidence and perspectives, <<LIVER INTERNATIONAL>>, 2020; 40 (6): 1262-1268. [doi:10.1111/liv.14441] [http://hdl.handle.net/10807/166544]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/166544
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 32
social impact